Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.
Pharming Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€9.90|
|52 Week High||€9.43|
|52 Week Low||€21.99|
|1 Month Change||-2.75%|
|3 Month Change||-15.57%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-40.72%|
Recent News & Updates
|PHAR||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how PHAR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PHAR performed against the US Market.
Stable Share Price: PHAR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PHAR's weekly volatility (6%) has been stable over the past year.
About the Company
|n/a||262||Simon de Vries||https://www.pharming.com|
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases.
Pharming Group Fundamentals Summary
|PHAR fundamental statistics|
Is PHAR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PHAR income statement (TTM)|
|Cost of Revenue||€18.61m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||0.042|
|Net Profit Margin||15.36%|
How did PHAR perform over the long term?See historical performance and comparison
Is Pharming Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHAR ($9.9) is trading below our estimate of fair value ($10.14)
Significantly Below Fair Value: PHAR is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: PHAR is good value based on its PE Ratio (20.3x) compared to the US Biotechs industry average (25.1x).
PE vs Market: PHAR is poor value based on its PE Ratio (20.3x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: PHAR is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: PHAR's PB Ratio (3.3x) is in line with the US Biotechs industry average.
How is Pharming Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHAR's forecast earnings growth (34.8% per year) is above the savings rate (2%).
Earnings vs Market: PHAR's earnings (34.8% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PHAR's revenue (23.2% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: PHAR's revenue (23.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PHAR's Return on Equity is forecast to be high in 3 years time
How has Pharming Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHAR has high quality earnings.
Growing Profit Margin: PHAR's current net profit margins (15.4%) are lower than last year (22.7%).
Past Earnings Growth Analysis
Earnings Trend: PHAR has become profitable over the past 5 years, growing earnings by 52.9% per year.
Accelerating Growth: PHAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHAR had negative earnings growth (-34.2%) over the past year, making it difficult to compare to the Biotechs industry average (4.9%).
Return on Equity
High ROE: PHAR's Return on Equity (16.1%) is considered low.
How is Pharming Group's financial position?
Financial Position Analysis
Short Term Liabilities: PHAR's short term assets (€211.1M) exceed its short term liabilities (€40.2M).
Long Term Liabilities: PHAR's short term assets (€211.1M) exceed its long term liabilities (€139.5M).
Debt to Equity History and Analysis
Debt Level: PHAR's debt to equity ratio (74.4%) is considered high.
Reducing Debt: PHAR's debt to equity ratio has reduced from 82.2% to 74.4% over the past 5 years.
Debt Coverage: PHAR's debt is well covered by operating cash flow (37.9%).
Interest Coverage: PHAR earns more interest than it pays, so coverage of interest payments is not a concern.
What is Pharming Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PHAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PHAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHAR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHAR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHAR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Simon de Vries (62 yo)
Dr. Sijmen De Vries, also known as Simon, M.D., M.B.A., has been the Chief Executive Officer of Pharming Group NV since November 3, 2008 and also serves as its Executive Director. He serves as President at...
CEO Compensation Analysis
Compensation vs Market: Simon's total compensation ($USD3.01M) is about average for companies of similar size in the US market ($USD2.35M).
Compensation vs Earnings: Simon's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: PHAR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: PHAR's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pharming Group N.V.'s employee growth, exchange listings and data sources
- Name: Pharming Group N.V.
- Ticker: PHAR
- Exchange: NasdaqGM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €542.744m
- Listing Market Cap: €636.948m
- Shares outstanding: 646.12m
- Website: https://www.pharming.com
Number of Employees
- Pharming Group N.V.
- Darwinweg 24
- 2333 CR
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 22:54|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.